# What the early rat comparison found about glucose and insulin

- Article ID: research-121
- Product: Fragment 176-191 (fragment-176-191-435)
- Canonical page: https://heritagebiolabs.com/research-library/articles/121-what-the-early-rat-comparison-found-about-glucose-and-insulin
- Product collection: https://heritagebiolabs.com/research-library/products/fragment-176-191
- Product page: https://heritagebiolabs.com/product/fragment-176-191-435
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1978, 1986, 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids linked by peptide bonds. Removing amino acids from one end can change how a peptide behaves. Fragment 176–191 is the last 16 residues of the mature human growth hormone chain. An older primary study directly included a synthetic version of this sequence in a comparison of six fragments. The researchers asked which pieces of the hormone’s tail could change glucose and insulin measures in rats. [1, 2]

The six peptides ended at the same position in growth hormone and started at different positions. The authors reported that the versions starting at 172, 176, 177 and 178 produced a short-lived rise in blood glucose and a longer rise in blood insulin under the tested conditions. Versions beginning at 179 or 180 showed no activity in those tests. The comparison illustrates how removing a small number of amino acids can alter the response measured in a particular experiment. [1]

The study also examined how the animals responded to insulin after exposure to peptides containing the sequence from position 178 through 191. The authors reported reduced insulin sensitivity in that part of their experiments. These observations concern laboratory rats, a specific experimental design and a short observation window. The paper supplies direct animal evidence about a fragment labeled with the native numbering. [1]

Later researchers studied a derivative with tyrosine at the beginning, called AOD-9604. Its different first amino acid and its own study conditions matter when comparing results. The glucose and insulin findings from 1978 cannot establish the size or direction of a human response to either material. Their value is in showing what the early experiment actually measured across several neighboring sequences. [1, 2, 3]

## Sources

1. F. M. Ng and J. Bornstein. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. American Journal of Physiology (publication 1978-05). <https://pubmed.ncbi.nlm.nih.gov/645904/>
2. UniProt Consortium. GH1 - Somatotropin - Homo sapiens (Human). UniProtKB P01241 (publication 1986-07-21, record updated 2026-11-04). <https://www.uniprot.org/uniprotkb/P01241/entry>
3. U.S. Food and Drug Administration. FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate). Pharmacy Compounding Advisory Committee briefing (publication 2024-12-04). <https://www.fda.gov/media/183584/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 025 - Fragment 176-191 and GHK-Cu.docx; article 121; content SHA-256 bbbaf1477f2b5381c9ff3d319882a360917af1bf4a8e15f1047185909e67a965.
